ArticlePloS one2009
Biological convergence of cancer signatures.
Article in PloS one, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Clinical value of prognosis gene expression signatures in colorectal cancer: a systematic review.PloS one · 2012Pooled it
- Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis.Genome biology · 2013Trial
- Gene signatures for cancer research: A 25-year retrospective and future avenues.PLoS computational biology · 2024Article
- A triple hormone receptor ER, AR, and VDR signature is a robust prognosis predictor in breast cancer.Breast cancer research : BCR · 2024Article
- ZNF92, an unexplored transcription factor with remarkably distinct breast cancer over-expression associated with prognosis and cell-of-origin.NPJ breast cancer · 2022Article
- Strategies to avoid treatment-induced lineage crisis in advanced prostate cancer.Nature reviews. Clinical oncology · 2017Review
- Tamoxifen therapy benefit predictive signature coupled with prognostic signature of post-operative recurrent risk for early stage ER+ breast cancer.Oncotarget · 2015Article
- Upregulation of adenylate cyclase 3 (ADCY3) increases the tumorigenic potential of cells by activating the CREB pathway.Oncotarget · 2013Article
- Article
- Cancer develops, progresses and responds to therapies through restricted perturbation of the protein-protein interaction network.Integrative biology : quantitative biosciences from nano to macro · 2012Article
- Improving biomarker list stability by integration of biological knowledge in the learning process.BMC bioinformatics · 2012Article
- Effect of size and heterogeneity of samples on biomarker discovery: synthetic and real data assessment.PloS one · 2012Article
- Do two machine-learning based prognostic signatures for breast cancer capture the same biological processes?PloS one · 2011Article
- Signaling pathways in breast cancer metastasis - novel insights from functional genomics.Breast cancer research : BCR · 2011Review
- Translating tumor antigens into cancer vaccines.Clinical and vaccine immunology : CVI · 2011Review
- Biological reprogramming in acquired resistance to endocrine therapy of breast cancer.Oncogene · 2010Article
- Identification of a panel of ten cell surface protein antigens associated with immunotargeting of leukemias and lymphomas by peripheral blood gammadelta T cells.Haematologica · 2010Article
- Piwil2 expressed in various stages of cervical neoplasia is a potential complementary marker for p16.American journal of translational research · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gene expression profiling has identified cancer prognostic and predictive signatures with superior performance to conventional histopathological or clinical parameters. Consequently, signatures are being incorporated into clinical practice and will soon influence everyday decisions in oncology. However, the slight overlap in the gene identity between signatures for the same cancer type or condition raises questions about their biological and clinical implications. To clarify these issues, better understanding of the molecular properties and possible interactions underlying apparently dissimilar signatures is needed. Here, we evaluated whether the signatures of 24 independent studies are related at the genome, transcriptome or proteome levels. Significant associations were consistently observed across these molecular layers, which suggest the existence of a common cancer cell phenotype. Convergence on cell proliferation and death supports the pivotal involvement of these processes in prognosis, metastasis and treatment response. In addition, functional and molecular associations were identified with the immune response in different cancer types and conditions that complement the contribution of cell proliferation and death. Examination of additional, independent, cancer datasets corroborated our observations. This study proposes a comprehensive strategy for interpreting cancer signatures that reveals common design principles and systems-level properties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.